Correction by Adenovirus-Mediated CFTR Gene Transfer |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
Human tracheal gland serous (HTGS) cells are now considered one principal pulmonary target for the
gene therapy of cystic fibrosis (CF). We developed a CF tracheal gland serous cell line, CF-KM4, obtained
by the transformation of primary cultures of CF tracheal gland serous cells homozygous for the
F508
mutation by using the wild-type SV40 virus. This cell line retained epithelial and secretory features of the
native CF-HTGS cells in primary culture, namely, presence of cytokeratin, constitutive secretion of secretory leukocyte proteinase inhibitor, absence of responsiveness to carbachol and isoproterenol, and defective
cyclic adenosine monophosphate-dependent chloride channel activity. Adenovirus-mediated CF transmembrane conductance regulator (CFTR) gene transfer into CF-KM4 cells corrected the defective chloride
channel activity as well as the responsiveness to adrenergic and cholinergic agonists. In contrast, control
transfection using adenovirus-mediated
-galactosidase gene transfer was totally ineffective. In conclusion, these results present a stable CF tracheal gland cell line that has retained its epithelial and CF-specific
defective secretory characteristics which are corrected after CFTR gene transfer. This cell line therefore appears to be a useful tool for large-scale molecular and cellular pharmacologic investigations designed to
test potential therapies of the disease CF.
| |
Introduction |
|---|
|
|
|---|
Cystic fibrosis (CF) is the most common lethal genetic disease in the Caucasian population. It is characterized by a general exocrinopathy, the pulmonary syndrome of which (mucus hypersecretion and infection) still leads to death. The most characteristic feature of CF is the persistent colonization by Pseudomonas aeruginosa of the airways of CF patients. CF is caused by mutations in a gene encoding a membrane protein called CF transmembrane conductance regulator (CFTR), which was proved to possess a cyclic adenosine monophosphate (cAMP)-dependent chloride channel activity (1).
Using immunocytochemistry and in situ hybridization techniques, it was shown that the serous component of the submucosal bronchotracheal glands expresses a very high level of CFTR in comparison with the other bronchial epithelial cell types (2). Human tracheal gland serous (HTGS) cells actively participate in the local defense of the airways by secreting antibacterial proteins such as lactoferrin, lysozyme, and the secretory leukocyte protease inhibitor (SLPI) (3). Because HTGS cells (1) strongly express CFTR and (2) participate in the antibacterial defense of the lung, they are considered one of the principal target pulmonary cell types of the disease CF (4).
We successfully developed techniques for culturing HTGS cells from normal and CF patients (5). In culture, these cells were shown to be of the serous type (5) and to have retained most of their in vivo epithelial and secretory characteristics, such as secretion of the three specific serous secretory markers: SLPI, lysozyme, and lactoferrin. These cells were also shown to express high levels of CFTR (8, 9). However, there are enormous limitations due to the rarity of available CF lung tissue and to difficulties in performing CF-HTG cell cultures from highly infected surgical pieces.
Recent advances in molecular biology and gene transfer technology render strategies possible in the gene therapy of this disease (10). One of the most promising transfer vectors is currently a recombinant adenovirus, defective
for the early replicative E1 gene. Adenovirus-mediated
transfer of CFTR complementary DNA (cDNA) into isolated epithelial CF cells in culture has demonstrated a correction of cAMP-dependent chloride conductance dysfunction (11, 12), and this CFTR cDNA-containing adenovirus
was used successfully in cotton rats (10), monkeys (13, 14),
and CF human volunteers (15). Several authors have tried
to determine the cell types that are transfected, by using adenovirus-mediated
-galactosidase (Ad-
-gal) gene transfer. Some described successful transfer into the surface epithelial cells (15, 16). On the contrary, others showed that
surface epithelial cells are inefficiently transfected but only
some duct cells and glands may be transfected (15, 17). Furthermore, none of these studies has addressed the effectiveness of the correction by CFTR gene transfer of the CF-associated defects of tracheal gland cells.
Faced with (1) the difficulty in obtaining surgical human tracheal pieces from CF patients (in sufficient size and number for reproducibility), and (2) the potential importance of the gland serous cells to be corrected, we developed an immortalized CF tracheal gland serous cell line, CF-KM4, that was shown to have retained serous secretory functions similar to those observed in the original CF-HTG cells (7). This cell line was used to study the effect of transfection with an adenovirus vector proposed in gene therapy of CF. We hereby showed an effective integration of the CFTR gene in the transfected cells, resulting in the appearance of cAMP-dependent low-conductance chloride channel activities as well as a complete correction of the defective cholinergic and adrenergic stimulation of protein secretion.
| |
Materials and Methods |
|---|
|
|
|---|
Materials
Epinephrine, isoproterenol, carbamoylcholine, adenosine-5'-triphosphate (ATP), forskolin, 3-isobutyl-1-methylxanthine (IBMX), and Dulbecco's modified Eagle's medium/ Ham's F12 mixture (DMEM/F12) were obtained from Sigma (St. Louis, MO). Ultroser G was from Biosepra (Villeneuve la Garenne, France). Anticytokeratin antibodies (KL1 clone) were obtained from Immunotech (Marseille, France), and anti-SV40 antibodies (MAB 990) were from Chemicon, Temecula, CA. The fluorescein isothiocyanate (FITC)-conjugate rabbit antimouse antibodies were from Dakopatts (Glostrup, Denmark). All other chemicals were of cell-culture grade.
Generation of a CF-HTG Cell Line
CF-HTGS cells, isolated from an individual carrying a
F508/
F508 mutation and undergoing pulmonary transplantation, were cultured as described in CELL CULTURE
CONDITONS, below. Subcultured cells were then grown in
six-well plates until 10 d after confluence, and each well
was infected with 500 µl of SV40 lysate (titer: 1 to 2 × 108
plaque-forming units/ml) for 30 min. Cells were then
rinsed twice with phosphate-buffered saline and fresh culture medium was added. After 3 d, the contents of each
dish were passaged onto 75-cm2 flasks. Within 2 wk, growing cell areas were detected and isolated using cloning
rings, and each isolated cell population was passaged first
in 24-well plates and then in 24-cm2 flasks. We ascertained
that the growing cells were immortalized because of the
complete inability of the nonimmortalized CF-HTGS cells
to divide at confluence. As a result, we obtained 12 different cell lines, which were screened and selected for their
epithelial and secretory features that were the closest to
those of the native CF-HTGS cells. Our selection criteria
were growth recovery after passaging, maintenance of the
ability to secrete the specific secretory marker SLPI, an
epithelial morphology, the presence of cytokeratin within
the cells, and the stability of all of these characteristics
whatever the number of passages. After selection, one of
the isolated cell lines, CF-KM4, was shown to have retained all of the above criteria.
Cell Culture Conditions
CF-HTG cells as well as the non-CF-HTG cell line MM-39 and the CF-KM4 cell line were cultured as previously described (18). Briefly, cells were maintained in a DMEM/ F12 mixture supplemented with 1% Ultroser G, 0.22 g/liter sodium pyruvate, and 8 g/liter glucose. Epinephrine (2.5 µM) was routinely added to the cell-culture medium to provide optimal growth and differentiation (19). The cells were passaged using 0.025% trypsin (GIBCO, Cergy Pontoise, France) and 0.02% ethlyenediaminetetraacetic acid and used at the third passage, 8 d after confluency, because of an extended differentiated state at that moment. Type 1 collagen-coated disposable tissue-culture flasks were used. At the end of all incubations with pharmacologic agents or virus, cell viability was assessed by measurement of lactate dehydrogenase (LDH) release in the incubation medium. LDH activity was measured using the Sigma lactate dehydrogenase kit. We routinely checked for the absence of mycoplasma in the primary culture of HTGS cells and in immortalized cell lines using the DNA fluorescent dye Hoechst 33258 as described in Reference 20.
CHO cells were generously obtained from J. R. Riordan and X. B. Chang (Mayo Clinic, Scottsdale, AZ) and cultured as detailed in Reference 21.
Immunocytochemistry
CF-KM4 cells were fixed for 30 min at
20°C with methanol and thereafter immunocytochemically examined with
mouse anticytokeratin antibodies (at a 1:500 dilution) and
anti-SV40 large T monoclonal antibodies (at 1:1,000 dilution). Both anticytokeratin and anti-SV40 large T antibodies were revealed with a goat antimouse antibody (at 1:
1,000 dilution) conjugated to FITC.
Polymerase Chain Reaction (PCR)
DNA was extracted from cells using standard techniques
(22). Approximately 200 ng of genomic DNA from each
pellet of cells was amplified by PCR. The PCR experiment
was performed using the following oligonucleotide synthetic primers: 5'-CACTCCTCTTCAAGACAAA-3' and
5'-CTGGATGAAGTCAAATATGG-3', both flanking the
F508 mutation. The thermal cycle profile consisted of (1)
denaturation for 60 s at 94°C, (2) primer annealing for 45 s
at 62°C, and (3) extension for 120 s at 72°C. The amplification was performed for 28 cycles. The amplification product (20 µl) was analyzed on polyacrylamide (10%) gel
electrophoresis (PAGE) (overnight at 300 V) and visualized under ultraviolet after ethidium bromide staining.
Cell Treatment with the Adenoviral Constructions
Ad-
-Gal and Ad-CFTR
The adenoviral constructions shuttle plasmids Ad-
-gal
and Ad-CFTR were built (10, 23) and kindly provided by
Transgene (Strasbourg, France). The vector preparations
(109 pfu/ml) were endotoxin-free. Confluent CF-KM4 cell
treatment consisted of exposure to 10 multiplicities of infection of Ad-
-gal or Ad-CFTR by cells for 24 h. Cells
with and without treatment were studied for PCR and
their electrophysiologic and pharmacologic properties immediately after this 24-h exposure to virus.
Single-Channel Patch-Clamp Recording
Cells were grown on glass coverslips under the conditions described above. Single-channel currents were recorded from cell-attached configuration. Cells were stimulated with 10 µM forskolin and 250 µm IBMX (dissolved in dimethyl sulfoxide to a final concentration of 0.1%). Experiments were performed at room temperature. Results were displayed conventionally with inward currents (outward flow of anions) indicated by downward deflections. In all the figures, dotted lines give the zero-current baselines when the channels were all in the closed state. Positive potentials indicate depolarization. Potentials were expressed as the bath potential minus the patch electrode potential. The pipette solution (pH 7.4) contained 150 mM NaCl, 2 mM MgCl2, and 10 mM N-tris[hydroxymethyl]methyl-2-aminoethanesulfonic acid (TES). The bath contained 145 mM NaCl, 4 mM KCl, 2 mM MgCl2, and 10 mM TES (pH 7.4). Other details appear elsewhere (9). For selectivity experiments, 150 mM NaCl were substituted either by 150 mM choline chloride or by 40 mM NaCl plus 110 mM sodium gluconate in the pipette solution. Data are presented as the means ± SD of n separate experiments.
Pharmacologic Stimulation of CF-KM4
CF-KM4 cells were grown onto 24-well plates, and 8 d after confluence they were rinsed for 1 h with DMEM/F12. After five 1-h washes, cells were exposed to 100 µM in DMEM/F12 of either carbachol, isoproterenol, or ATP. After a 30-min exposure, supernatants were collected for SLPI analysis. The effects of pharmacologic agents were analyzed by determining the SLPI relative secretory rate (SLPI S.R.), that is, SLPI secreted in the assay versus SLPI secreted in control wells in which vehicle solutions alone were added at the same times as the drugs were added to experimental wells. The mean ratio was calculated from quadruplicate assays. Each experiment was performed three times. Mean ± SD is indicated. SLPI was assayed by enzyme-linked immunosorbent assay (24).
| |
Results |
|---|
|
|
|---|
Characterization of the CF-KM4 Clone
One selection criterion of the CF-KM4 cell line was its homogeneous epithelial morphology. Phase-contrast microscopic photographs of CF-KM4 cells taken during the exponential growth phase and the stationary phase show that their morphology was typically epithelial in nature (Figure 1A). Like CF-HTGS cells, the CF-KM4 cells formed clusters of jointed adherent cells. At confluence, reached 8 d after seeding, the monolayer composed of tightly molded polygonal cells showed a mosaic morphology (Figure 1B). When examined for cytokeratin, all of the CF-KM4 cells were labeled with the anticytokeratin monoclonal antibody showing, as expected for typical epithelial cells, a strong cytoskeleton network inside the cells (Figure 1C). We also examined the expression of the SV40 large T antigen within the CF-KM4 cells using a monoclonal antibody specific for the large T antigen. CF-KM4 cells reacted positively with the antibody by a nuclear staining in 100% of the cells, indicating that the entire population of CF-KM4 cells was transformed (Figure 1D).
|
From the 12 clones we originally obtained (named CF-KM1 to CF-KM12) we selected the transformed CF-KM4 cell line presenting growth and epithelial characteristics, as deduced from the abovementioned features, similar to those of the genuine CF-HTG cells. The isolation and culture of CF-HTG cells have already been described in detail in a previous work (7), and we demonstrated the relatively short lifespan of the culture of these cells. Indeed, the effective passaging of these CF-HTG cells more than five or six times was, we found, impossible. In contrast, to date, we have been able to passage the CF-KM4 cells more than 20 times without any modification to their growth or secretory characteristics. All of the results we present here were obtained during the tenth passage and are completely identical to those of the fourth and also the seventeenth; and as observed for the non-CF-HTG cell line MM-39 (18), CF-KM4 cells did not undergo a "crisis period" between passages 10 and 20.
CFTR Transgene after Ad-CFTR Transfection
To visualize adenovirus-mediated CFTR gene transfer in
the CF-KM4 cell line, we looked for the presence of the
CFTR transgene by PCR analysis using primers spanning
the
F508 mutation of the gene. Used as controls, DNA
from the normal HTG cell line MM-39 as well as DNA extracted from a person heterozygous for the
F508 mutation were also amplified and run into the polyacrylamide
gel. The ethidium bromide-stained PAGE of the different
PCR products is shown in Figure 2. The 97-base pair (bp)
and 94-bp bands correspond to the normal and
F508
PCR products, respectively. The additional bands are heteroduplex forms due to competitive hybridization of the
mutant and the normal trends toward the end of the PCR reaction. Whereas in MM-39 cells PCR reaction shows the
presence of the normal form of CFTR, in CF-KM4 cells
only the
F508-mutated form is present. After adenovirus-mediated CFTR gene transfer, the 97- and 94-bp bands are
observed as well as the heteroduplex forms, indicating that
both the normal and the
F508-mutated genes are present
in the transfected cells.
|
Electrophysiologic Characterization of CF-KM4 Cells before and after Transfection with Ad-CFTR
Primary cultures of HTG cells highly express CFTR (8), which is detectable by its low-conductance chloride channel activity (9). To assess whether transformation with SV-40 may have affected CFTR function, we first performed cell-attached patch-clamp experiments to characterize the cAMP-activated CFTR chloride channel in the transformed non-CF MM-39 cells.
In control patch-clamp experiments with 150 mM NaCl
in the pipette
that is, in the absence of agonists of the
cAMP pathway
no spontaneous cell-attached channel
activity was recorded (n = 5). The addition to the bath of a
cAMP cocktail (10 µM forskolin plus 250 µM IBMX) caused
the activation of previously silent multiple CFTR-like
channels (four out of five experiments). Furthermore, in
cells incubated with the cAMP cocktail, spontaneous
channel activity was recorded in nine out of 10 experiments (Figure 3A1). Under both conditions, the currents
reversed at 0 mV (Figure 3C). Two sets of experiments
were then performed to ascertain the chloride selectivity
of the channels activated by cAMP agonists. With 150 mM
choline chloride in the pipette, similar CFTR-like channel activity was recorded in cAMP-treated MM-39 cells (two
out of three experiments). The reversal potential was close
to 0 mV (n = 2). With 40 mM NaCl and 110 mM sodium
gluconate in the pipette, channel activity that reversed at
28 ± 3 mV (n = 3) was detected in cAMP-treated MM-39
cells (not shown). Together, these experiments demonstrate the chloride selectivity of the channels activated in
cAMP-treated MM-39 cells. For comparison, Figures 3B
and 3C show a representative cell-attached recording of
CFTR channels from a CHO cell stably expressing CFTR,
in the presence of the cAMP cocktail in the bath. The current-voltage relationship and unitary conductance cAMP-activated chloride channels in MM-39 cells (9.2 ± 2.1 pS,
n = 13) were similar to those observed with CHO cells stably expressing CFTR (7 ± 0.8 pS, n = 4; Figure 3C) and to
those already described for the parental HTG cells (9) or
other preparations (21). Therefore, we concluded that in MM-39 cells the chloride channels activated on-cell by
cAMP can be identified as CFTR.
|
We thereafter performed cell-attached patch-clamp experiments to characterize the cAMP-activated chloride
channel in CF-KM4 and CF-KM4 transfected with either
Ad-
-gal or with Ad-CFTR. As for MM-39 cells, in all
control patch-clamp experiments no spontaneous cell-
attached channel activity was recorded in the absence of cAMP agonists (n = 9, pooled data). In the presence of
the cAMP cocktail, opening of CFTR channels was consistently observed only in the CF-KM4 cells transfected with
Ad-CFTR (Figure 3A4) but not in CF-KM4 cells (Figure
3A2) or CF-KM4 cells transfected with Ad-
-gal (Figure
3A3). The chloride channels activated in CF-KM4 cells
transfected with Ad-CFTR have a low unitary conductance of 9.2 ± 1.5 pS (n = 7, Figure 3C). As shown in Figure 3C, the I/V relationship was linear and very similar to
that measured using MM39 cells or transfected CHO cells.
Although we observed the activity of outwardly rectifying chloride channel in excised membrane patches in all the cell types tested here, including transfected CHO cells, no other channel activity (except CFTR) was recorded in cell-attached patch-clamp configurations. Especially, these large conductance outwardly rectifying chloride channel (ORCC)-like channels were not observed in cell-attached configuration, even in cAMP-treated cells (not shown). These observations further support our conclusion that CFTR was the only ionic channel activated by the cAMP pathway in MM-39 and transfected cells. These data demonstrate that CFTR gene transfer was successful and that the CFTR protein derived from the transgene had cAMP-dependent chloride channel activities and biophysical properties similar to those from the homologous non-CF cells (i.e., MM-39 cells and HTG cells; [9]) or from the well-established CHO cells stably expressing CFTR ([21] and Figure 3B).
Pharmacologic Stimulation of the CF-KM4 Cells before and after Transfection with Ad-CFTR
We previously showed that the SV40-transformed MM-39
cells respond to muscarinic (carbachol), adrenergic (isoproterenol), and nucleotidic (ATP) agonists by increases
in the secretion of the specific secretory marker SLPI (18).
The amplitudes of these increases at the optimal concentration of agonists (100 µM) are reported in Figure 4A for
comparison. They were, respectively, 75 ± 5, 64 ± 12, and
82 ± 10%. In contrast, CF-KM4 cells failed to be stimulated by the cholinergic (carbachol) or the
-adrenergic (isoproterenol) agonists. However, response to ATP was
conserved (Figure 4B). The mean effective dose of the action of ATP deduced from the dose-response curves (data
not shown) was 3 µM, a value similar to that found in normal HTG cells (25).
|
In Figure 4C are the responses to the same agonists of
CF-KM4 cells transfected with Ad-
-gal. Their secretory
pattern was found to be similar to that of nontransfected
CF-KM4 cells. In contrast, after adenovirus-mediated CFTR
gene transfer, a correction of the inability to respond to
carbachol and to isoproterenol was observed (Figure 4D).
The corrected responses, however, reached higher amplitudes (about 2-fold more) than those of the MM-39 cells.
Responses to ATP were not modified.
Of all the agonists tested at high concentrations (1 mM), none significantly altered basal release of LDH from CF-KM4 cells.
| |
Discussion |
|---|
|
|
|---|
In this work we have presented a transformed cell line of CF tracheal gland cells, CF-KM4, that has retained stable and epithelial characteristics similar to the original parental cells. This cell line also constitutively produced SLPI as the tracheal gland serous cells in primary culture (7) and in vivo (26). Furthermore, as is also the case with the parental cells, CF-KM4 cells are not responsive to adrenergic and cholinergic agonists. Consequently, CF-KM4 cells may represent an interesting tool for large-scale study of some pathophysiologic features of CF.
Several cell lines deriving from CF nasal explants or CF primary culture of bronchial cells from the surface epithelium have been developed because of their greater growth potential than primary cultures, giving increased cellular material to study (27). However, it is difficult to acknowledge these studies because the precise phenotype of these cell lines had never been described; that is, they do not appear to be of goblet-cell or ciliated-cell nature (both corresponding to over 90% of the total amount of surface epithelial cells). Therefore, their undetermined nature, or perhaps their insufficient state of differentiation, render them poorly suitable for examining abnormalities in the secretory dysfunction related to CFTR.
To carry out accurate investigations about the physiologic properties of CFTR at the molecular and cellular levels, we therefore focused on developing a CF respiratory
cell line from submucosal gland serous cells because (1)
they are the cells in which CFTR is expressed at the highest level in the human bronchus (2), and (2) it seemed necessary to establish a cell line with a defined phenotype and
with clear characteristics. CF-KM4 cells after transformation have retained similar properties to those of the parental cells, namely, presence of the
F508/
F508 mutated
CFTR genes, an absence of cAMP-dependent chloride
channels, and also an absence of a responsiveness to adrenergic and cholinergic agonists by an increase in the secretion of the specific serous-cell marker SLPI. These particular and CF-specific properties might not be a consequence of transformation because introduction of a normal CFTR
gene into the CF-KM4 cells corrected the cAMP-dependent chloride channel activity and the defective responsiveness to secretagogues to a level comparable with that
observed with the normal homologous cells. Thus, transformation may not have changed the typical CF features
of these cells.
Numerous data about CFTR gene transfer concerned pulmonary surface epithelial cells and were focused principally on the correction of the chloride transport defect, a characteristic feature of CF. However, most of this data is still conflicting. Zabner and colleagues have shown that low doses of adenovirus vectors carrying CFTR cDNA can correct defective chloride transport in culture human CF airway epithelial cells (30). On the other hand, inefficiency of gene transfer vector to CF airway epithelia of mice and humans was observed by Grubb and associates (17). It was suggested that this difference may disparately reflect the susceptibility to adenoviral transfection of the epithelial cell types studied in vivo (of columnar phenotype) and in vitro (of basal cell-like phenotype). Again, these discrepancies pinpoint all the care that must be taken when interpreting these results according to the model used.
In CF-KM4 cells, adenovirus-mediated CFTR gene
transfer led to correct expression of the transgene as we
observed the CFTR-associated chloride channel activity in
the transfected cells. The properties of the channel, cAMP
dependency and low conductance, were those expected for
CFTR and were similar to the ones found in the non-CF homologous cells: the normal HTG cells (9) and the transformed MM-39 cells, the Calu-3 cell line thought to be also
glandular serous cells (31), as well as the ones sufficiently
described in the literature (21). This transfection was also
shown to lead to correction of specific defects of CF cells,
namely, an absence of chloride transport and of
-adrenergic and cholinergic stimulation of secretion. This potential of correction of CF defects by adenovirus-mediated
CFTR gene transfer that we showed in gland cells, together with the study of Pilewski and coworkers, who showed a high efficiency of transfection in tracheal glands
using adenovirus-mediated
-galactosidase gene transfer
in xenografts (32), argue in favor of a possible use of these
recombinant adenoviral vectors for gene therapy.
Besides the defect in chloride secretion by CF epithelial
cells, CFTR is also thought to be implicated in macromolecule secretion, and there is increasing evidence that a defect in submucosal gland secretion contributes to the airway pathology of CF. The cAMP-dependent secretory
process is indeed lost in the cAMP-mediated fluid secretion in CF (33). One of the consequences is that it may
then significantly reduce the water content of gland secretions. The resulting change in viscosity would contribute to
the accumulation of airway mucus that is a characteristic
of this disease.
-Adrenergic response to agonists, which
increases cAMP level, has been shown to be defective not
only for secretion of chloride but also for secretion of macromolecules. McPherson and colleagues (34) have shown a
defective
-adrenergic response in the secretion of amylase and of glycoconjuguates by CF submandibular acinar
cells, and evidence for a direct implication of CFTR on
mucin secretion was established when CF-submandibular
acinar cells were treated with antibody directed against
CFTR (35). We showed previously that, in contrast to the
normal cells, primary culture of CF tracheal gland cells
was insensitive to neurotransmitters that may act through
adrenergic and cholinergic receptors for their secretion of
the specific secretory marker SLPI (7). CF-KM4 were also found here to be unresponsive to adrenergic and cholinergic agonists. This defective cholinergic and adrenergic
receptor-dependent secretion was corrected after CFTR
gene transfer but not after
-galactosidase gene transfer.
These results are in agreement with those reported by
Mergey and associates (36), who stated that gene transfer to CF fetus cell lines restored defective cAMP-dependent
secretion not only of chloride ions but also of glycoconjugates. It has been shown that the second messenger systems do not appear to be modified in CF cells, and it was
therefore suggested that an as-yet-unidentified system
subsequent to second messengers may be involved in the
CF defect.
Moreover, one question that consequently remains is why CFTR may interact with the adrenergic and cholinergic receptor activation and not with the purinergic receptor functioning. This difference might indicate either a difference in second-messenger systems involved by this receptor, or of systems distant to second messengers that might be specific for the purinoceptor.
An actual and troublesome side effect of adenovirus-mediated gene transfer is the immune response by the host (37, 38). The cotton-rat model (39) confirmed the role of cellular immunity in the biology of recombinant adenovirus-mediated gene therapy in the lung and suggested that modifications in the design of recombinant adenoviruses will be useful in improving the potential of this technology in gene therapy of CF, such as high levels of transgene expression, more stable expression of the transgene, and less expression of the remaining early and late gene of the adenovirus. When tracheal gland cells were placed in a proinflammatory situation, they were shown to acquire a CF-like phenotype (40). Thus, in the present study, if adenovirus-mediated gene transfer may have induced inflammatory reactions, the corrected CF cells would have shifted to a CF-like phenotype and the gain from the transfer would have been lost. Because a clear responsiveness to secretagogues was observed after gene transfer, it is therefore unlikely that the current constructions we used induced inflammatory-like reactions by the cells. Although this observation is interesting, it remains speculative and additional work must be designed and carried out to clear this crucial point. This appears important to us because HTG cells were recently shown to participate actively in the cytokine network of the lung (41) and may be able to modulate the inflammatory process of the bronchotracheal tree.
In conclusion, this is the first demonstration showing the effectiveness of CF tracheal gland cells to be corrected by adenovirus-mediated CFTR gene transfer both in chloride and also in protein secretion. Because tracheal gland serous cells are a major site of CFTR expression in the human bronchus, the newly established CF-KM4 cell line can be considered an appropriate model to test at the cellular and molecular level the effects of gene transfer. This cell line can therefore also be helpful for designing and testing the newer generations of adenovirus vectors for gene therapy of CF.
| |
Footnotes |
|---|
Address correspondence to: Marc D. Merten, Groupe de Recherche sur les Glandes Exocrines, Faculté de Médecine, 27 Boulevard Jean Moulin, F-13385 Marseille Cedex 05, France. E-mail: grge{at}medecine.univ-mrs.fr
(Received in original form February 19, 1998 and in revised form August 25, 1998).
* Permanent address: Laboratorie de Physiologie des Regulations Cellulaires, Universite de Poitiers, UMR 6558, 40 Av du recteur Pineau, 86022 Poitiers, France.Acknowledgments: The authors thank Dr. D. Métras (Marseille, Hopital de la Timone, France), Dr. P. Y. Brichon, Dr. I. Pin, and J. Quentin (Grenoble, Med. Univ., France) for providing normal and CF surgical tracheal pieces. The authors acknowledge C. Vo Van and M. A. Voelckel for having performed the PCR experiments. This work was supported by grants from the Association Française de Lutte contre la Mucoviscidose (AFLM). One author (W.K.) holds a fellowship from AFLM and from FRM (Fondation pour la Recherche Médicale). The authors thank Timothy Ferguson for his help with the English text and Florence Zamkotsian for technical assistance.
| |
References |
|---|
|
|
|---|
1.
Riordan, J. R.,
J. M. Rommens,
B. S. Kerem,
N. Alon,
R. Rozmahel,
Z. Grzelczak,
J. Zielenski,
S. Lok,
N. Plavsic,
J. L. Chou,
M. L. Drumm,
M. C. Iannuzzi,
F. S. Collins, and
L. C. Tsui.
1989.
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
Science
245:
1066-1073
2. Engelhardt, J. F., J. R. Yankaskas, S. A. Ernst, Y. P. Yang, C. R. Marino, R. C. Boucher, J. A. Cohn, and J. M. Wilson. 1992. Submucosal glands are the predominant site of CFTR expression in human bronchus. Nat. Genet. 2: 240-246 [Medline].
3. Basbaum, C. B., B. Jany, and W. E. Finkbeiner. 1990. The serous cell. Annu. Rev. Physiol. 52: 97-113 [Medline].
4. Merten, M., and F. Becq. 1995. Cystic fibrosis: which pulmonary cells have to be studied first? Medecine/Sciences 11:1442-1446.
5. Tournier, J. M., M. D. Merten, Y. Meckler, J. Hinnrasky, C. Fuchey, and E. Puchelle. 1990. Culture and characterization of human tracheal gland cells. Am. Rev. Respir. Dis. 141: 1280-1288 [Medline].
6. Merten, M. D. 1996. Human tracheal gland cells in primary culture. In Methods in Molecular Medicine: Cell Culture Protocols. E. Jones, editor. Humana Press, Totowa, NJ. 211-216.
7.
Merten, M., and
C. Figarella.
1993.
Constitutive hypersecretion and insensitivity to neurotransmitters by cystic fibrosis tracheal gland cells.
Am. J. Physiol.
264:
L93-L99
8. Renaud, W., M. Merten, and C. Figarella. 1994. Increased coexpression of CFTR and S100 calcium binding proteins MRP8 and MRP14 in cystic fibrosis human tracheal gland cells. Biochem. Biophys. Res. Commun. 201: 1518-1525 [Medline].
9. Becq, F., M. D. Merten, M. A. Voelckel, M. Gola, and C. Figarella. 1993. Characterization of cAMP-dependent CFTR-chloride channels in human tracheal gland cells. FEBS Lett. 321: 73-78 [Medline].
10. Rosenfeld, M. A., K. Yoshimura, B. C. Trapnell, K. Yoneyama, E. R. Rosenthal, W. Dalemans, M. Fukayama, J. Bargon, L. E. Stier, L. Stratford-Perricaudet, M. Perricaudet, W. B. Guggino, A. Pavirani, J. P. Lecoq, and R. J. Crystal. 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68: 143-155 [Medline].
11. Rich, D. P., L. A. Couture, L. M. Cardoza, V. M. Guiggio, D. Armentano, P. C. Espino, K. Hebir, M. J. Welsh, A. E. Smith, and R. J. Gregory. 1993. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Gene Ther. 4: 461-476 .
12. Johnson, L. G., J. C. Olsen, B. Sarcadi, K. L. Moore, R. Swanstrom, and R. C. Boucher. 1992. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat. Genet. 2: 21-25 [Medline].
13. Bout, A., J. L. Imler, H. Schultz, M. Perricaudet, G. Baskin, P. Herbrink, D. Valerio, and A. Pavirani. 1994. In vivo adenovirus-mediated gene transfer of human CFTR cDNA to rhesus monkey airway epithelium: efficacy, toxicity, and safety. Gene Ther. 1: 385-394 [Medline].
14. Englehardt, J. F., R. H. Simon, Y. Yang, M. Zepeda, S. Weber-Pendleton, B. Doranz, M. Grossman, and J. M. Wilson. 1993. Adenovirus mediated transfer of the CFTR gene to lung of non human primates: biological efficacy study. Hum. Gene Ther. 4: 759-769 [Medline].
15. Knowles, M. R., K. Hohneker, Z. Zhou, J. C. Olsen, T. L. Noah, P. C. Hu, M. W. Leigh, J. F. Englehardt, L. J. Edwards, K. R. Jones, M. Grossman, J. M. Wilson, L. G. Johnson, and R. C. Boucher. 1995. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333: 821-833 .
16. Zabner, J., L. A. Couture, R. J. Gregory, S. M. Graham, A. E. Smith, and M. J. Welsh. 1993. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75: 207-216 [Medline].
17. Grubb, B. R., R. J. Pickles, H. Ye, J. R. Yankaskas, R. N. Vick, J. F. Engelhardt, J. M. Wilson, L. G. Johnson, and R. C. Boucher. 1994. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 371: 803-806 .
18. Merten, M., W. Kammouni, W. Renaud, F. Birg, M. G. Mattei, and C. Figarella. 1996. A transformed human tracheal gland cell line, MM-39, that retains serous secretory functions. Am. J. Respir. Cell Mol. Biol. 15: 520-528 [Abstract].
19. Merten, M. D., J. M. Tournier, Y. Meckler, and C. Figarella. 1993. Epinephrine promotes growth and differentiation of human tracheal gland cells in culture. Am. J. Respir. Cell Mol. Biol. 9: 172-178 .
20. Chen, T. R.. 1977. In situ detection of Mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp. Cell. Res. 104: 255-262 [Medline].
21. Hanrahan, J. W., J. A. Tabcharani, F. Becq, C. J. Mathews, O. Augustinas, T. J. Jensen, X. B. Chang, and J. R. Riordan. 1995. Function and dysfunction of the CFTR chloride channel. In Ion Channels and Genetic Diseases. Society of General Physiologists Symposium Series, Vol. 50. D. C. Dawson and R. A. Frizzell, editors. Rockefeller University Press, New York. 125- 137.
22. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. C. Nolan, editor. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
23. Stratford-Perricaudet, L. D., I. Makeh, M. Perricaudet, and P. Briand. 1992. Widespread long-term gene transfer to mouse skeletal muscles and heart. J. Clin. Invest. 90: 626-630 .
24. Tournier, J. M., J. Jacquot, P. Sadoul, and J. G. Bieth. 1983. Noncompetitive enzyme immunoassay for the measurement of bronchial inhibitor in biological fluids. Anal. Biochem. 131: 345-350 [Medline].
25.
Merten, M.,
J. P. Breittmayer,
C. Figarella, and
C. Frelin.
1993.
ATP and
UTP increase the secretion of the bronchial inhibitor by human tracheal
gland cells in culture.
Am. J. Physiol.
265:
L479-L484
26. Kramps, J., C. Franken, and J. Dijkman. 1981. Localisation of low molecular weight protease inhibitor in serous secretory cells of the respiratory tract. J. Histochem. Cytochem. 29: 712-720 [Abstract].
27.
Schwiebert, E. M.,
L. P. Cid-Soto,
D. Stafford,
M. Carter,
C. J. Blaisdell,
P. L. Zeitlin,
W. B. Guggino, and
G. R. Cutting.
1998.
Analysis of ClC-2
channels as an alternative pathway for chloride conduction in cystic fibrosis airway cells.
Proc. Natl. Acad. Sci. USA
95:
3879-3884
28.
Jiang, X.,
W. G. Hill,
J. M. Pilewski, and
O. A. Weisz.
1997.
Glycosylation
differences between a cystic fibrosis and rescued airway cell line are not
CFTR dependent.
Am. J. Physiol.
273:
L913-L920
29. Wei, X., R. Eisman, J. Xu, A. D. Harsch, A. E. Mulberg, C. L. Bevins, M. C. Glick, and T. F. Scanlin. 1996. Turnover of the cystic fibrosis transmembrane conductance regulator (CFTR): slow degradation of wild-type and delta F508 CFTR in surface membrane preparations of immortalized airway epithelial cells. J. Cell. Physiol. 168: 373-384 [Medline].
30. Zabner, J., L. A. Couture, A. E. Smith, and M. J. Welsh. 1994. Correction of cAMP-stimulated fluid secretion in cystic fibrosis airway epithelia: efficiency of adenovirus-mediated gene transfer in vitro. Hum. Gene Ther. 5: 585-593 [Medline].
31.
Haws, C.,
W. E. Finkbeiner,
J. H. Widdicombe, and
J. J. Wine.
1994.
CFTR
in Calu-3 human airway cells: channel properties and role in cAMP-activated Cl-conductance.
Am. J. Physiol.
266:
L502-L512
32.
Pilewski, J. M.,
J. F. Engelhardt,
J. E. Bavaria,
L. R. Kaiser,
J. M. Wilson, and
S. M. Albeda.
1995.
Adenovirus-mediated gene transfer to human
bronchial submucosal glands using xenografts.
Am. J. Physiol.
268:
L657-L665
33.
Jiang, C.,
W. E. Finkbiner,
J. H. Widdicombe, and
S. S. Miller.
1997.
Fluid
transport across cultures of human tracheal glands is altered in cystic fibrosis.
J. Physiol.
501:
637-647
34.
McPherson, M. A., R. L. Dormer, N. A. Bradbury, J. A. Dodge, and M. C. Goodchild. 1986. Defective
-adrenergic secretory responses in submandibular acinar cells from cystic fibrosis patient. Lancet II:1007-1008.
35. Mills, C. L., M. M. C. Pereira, R. L. Dormer, and M. A. McPherson. 1992. An antibody against a CFTR-derived synthetic peptide, incorporated into living submandibular cells, inhibits beta-adrenergic stimulation. Biochem. Biophys. Res. Commun. 188: 1146-1152 [Medline].
36.
Mergey, M.,
M. Lemnaouar,
D. Veissiere,
M. Perricaudet,
D. C. Gruenert,
J. Picard,
J. Capeau,
M. C. Brahimi-Horn, and
A. Paul.
1995.
CFTR gene
transfer corrects defective glycoconjuguate secretion in human CF epithelial tracheal cells.
Am. J. Physiol.
269:
L855-L864
37.
Yang, Y.,
F. A. Nunes,
K. Berencsi,
E. E. Furth,
E. Gönczöl, and
J. M. Wilson.
1994.
Cellular immunity to viral antigens limits E1 deleted adenovirus
for gene therapy.
Proc. Natl. Acad. Sci. USA
91:
4407-4411
38. McElvaney, N. G., and R. G. Crystal. 1995. IL6 release and airway administration of human CFTR cDNA adenovirus vector. Nature Med. 1: 182-184 [Medline].
39. Engelhardt, J. F., L. Litzky, and J. M. Wilson. 1994. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5: 1217-1229 [Medline].
40. Kammouni, W., C. Figarella, N. Baeza, S. Marchand, and M. Merten. 1997. Pseudomonas aeruginosa lipopolysaccharide induces CF-like alteration of protein secretion by human tracheal gland cells. Biochem. Biophys. Res. Commun. 241: 305-311 [Medline].
41. Kammouni, W., C. Figarella, S. Marchand, and M. D. Merten. 1997. Altered cytokine production by cystic fibrosis tracheal gland serous cells. Infect. Immun. 15: 125-128 .
This article has been cited by other articles:
![]() |
F. Delavoie, M. Molinari, M. Milliot, J.-M. Zahm, C. Coraux, J. Michel, and G. Balossier Salmeterol Restores Secretory Functions in Cystic Fibrosis Airway Submucosal Gland Serous Cells Am. J. Respir. Cell Mol. Biol., April 1, 2009; 40(4): 388 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Granio, C. Norez, K. J. D. Ashbourne Excoffon, P. H. Karp, M. Lusky, F. Becq, P. Boulanger, J. Zabner, and S.-S. Hong Cellular Localization and Activity of Ad-Delivered GFP-CFTR in Airway Epithelial and Tracheal Cells Am. J. Respir. Cell Mol. Biol., December 1, 2007; 37(6): 631 - 639. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Gaden, L. Franqueville, M. K. Magnusson, S. S. Hong, M. D. Merten, L. Lindholm, and P. Boulanger Gene Transduction and Cell Entry Pathway of Fiber-Modified Adenovirus Type 5 Vectors Carrying Novel Endocytic Peptide Ligands Selected on Human Tracheal Glandular Cells J. Virol., July 1, 2004; 78(13): 7227 - 7247. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Gaden, L. Franqueville, S. S. Hong, V. Legrand, C. Figarella, and P. Boulanger Mechanism of Restriction of Normal and Cystic Fibrosis Transmembrane Conductance Regulator-Deficient Human Tracheal Gland Cells to Adenovirus Infection and Ad-Mediated Gene Transfer Am. J. Respir. Cell Mol. Biol., November 1, 2002; 27(5): 628 - 640. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Allo, P. Midoux, M. Merten, E. Souil, J. Lipecka, C. Figarella, M. Monsigny, P. Briand, and I. Fajac Efficient Gene Transfer into Human Normal and Cystic Fibrosis Tracheal Gland Serous Cells with Synthetic Vectors Am. J. Respir. Cell Mol. Biol., February 1, 2000; 22(2): 166 - 175. [Abstract] [Full Text] |
||||
![]() |
A. Saleh, C. Figarella, W. Kammouni, S. Marchand-Pinatel, A. Lazdunski, A. Tubul, P. Brun, and M. D. Merten Pseudomonas aeruginosa Quorum-Sensing Signal Molecule N-(3-Oxododecanoyl)-L-Homoserine Lactone Inhibits Expression of P2Y Receptors in Cystic Fibrosis Tracheal Gland Cells Infect. Immun., October 1, 1999; 67(10): 5076 - 5082. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Becq, Y. Mettey, M. A. Gray, L. J. V. Galietta, R. L. Dormer, M. Merten, T. Metaye, V. Chappe, C. Marvingt-Mounir, O. Zegarra-Moran, et al. Development of Substituted Benzo[c]quinolizinium Compounds as Novel Activators of the Cystic Fibrosis Chloride Channel J. Biol. Chem., September 24, 1999; 274(39): 27415 - 27425. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |